Nieuwscentrum

jan 25, 2021

Philips’ resultaten vierde kwartaal en jaarresultaat 2020


Philips behaalt in het vierde kwartaal een omzet van EUR 6,0 miljard, met een toename van de vergelijkbare omzet van 7%; resultaat uit doorlopende activiteiten neemt toe naar EUR 608 miljoen, gecorrigeerde EBITA-marge stijgt met 110 basispunten naar 19,0% en operationele kasstroom neemt toe naar EUR 1.305 miljoen

Kerncijfers vierde kwartaal

  • De omzet bedroeg EUR 6,0 miljard, met een groei van de vergelijkbare omzet van 7%
  • De vergelijkbare orderontvangst nam toe met 7%
  • Het resultaat uit doorlopende activiteiten nam toe naar EUR 608 miljoen, vergeleken met EUR 550 miljoen in het vierde kwartaal van 2019
  • De gecorrigeerde EBITA-marge nam toe naar 19,0% van de omzet, vergeleken met 17,9% van de omzet in het vierde kwartaal van 2019
  • Het bedrijfsresultaat nam toe naar EUR 795 miljoen, vergeleken met EUR 730 miljoen in het vierde kwartaal van 2019
  • WpA uit doorlopende activiteiten (verwaterd) bedroeg EUR 0,66; de gecorrigeerde WpA nam toe naar EUR 0,94, vergeleken met EUR 0,83 in het vierde kwartaal van 2019
  • De operationele kasstroom verbeterde naar EUR 1.305 miljoen, vergeleken met EUR 1.271 miljoen in het vierde kwartaal van 2019
  • De vrije kasstroom verbeterde naar EUR 1.055 miljoen, vergeleken met EUR 959 miljoen in het vierde kwartaal van 2019

Kerncijfers gehele jaar

  • De omzet bedroeg EUR 19,5 miljard, met een groei van de vergelijkbare omzet van 3%
  • De vergelijkbare orderontvangst nam toe met 9%
  • Het resultaat uit doorlopende activiteiten nam toe naar EUR 1.205 miljoen, vergeleken met EUR 1.192 miljoen in 2019
  • De aangepaste EBITA-marge bedroeg 13,2% van de omzet, in lijn met 2019
  • Het bedrijfsresultaat nam toe naar EUR 1.542 miljoen, vergeleken met 1.644 miljoen in 2019
  • WpA uit doorlopende activiteiten (verwaterd) bedroeg EUR 1,31; de gecorrigeerde WpA was EUR 1,98, in lijn met 2019
  • De operationele kasstroom verbeterde naar EUR 2.777 miljoen, vergeleken met EUR 2.031 miljoen in 2019
  • De vrije kasstroom verbeterde naar EUR 1.852 miljoen, vergeleken met EUR 1.053 miljoen in 2019
  • Voorgesteld dividend van EUR 0,85 per aandeel, in contanten of in aandelen naar keuze van de aandeelhouder

 

Frans van Houten, CEO van Koninklijke Philips:


"Tegen de achtergrond van de aanhoudende COVID-19 pandemie, bleven we zorgverleners en medisch personeel ondersteunen bij het verlenen van zowel acute COVID-19 zorg als reguliere gezondheidszorg. In het kwartaal ging Philips 25 nieuwe strategische samenwerkingsverbanden aan met ziekenhuizen in de VS, Europa en Azië, om hen te helpen hun klinische en operationele doelen te bereiken met onze geïntegreerde oplossingen. We ondersteunden ook consumenten thuis met telezorgoplossingen zoals teletandheelkunde en bewaking op afstand.

Ik ben verheugd dat we, als gevolg van deze inspanningen, in het kwartaal een vergelijkbare omzetgroei van 7% voor de Groep en een vergelijkbare groei van de orderontvangst van 7% hebben gerealiseerd. De gecorrigeerde EBITA-marge verbeterde met 110 basispunten en we behaalden een sterke vrije kasstroom van EUR 1.055 miljoen.

We hebben dit kwartaal verschillende nieuwe producten en oplossingen gelanceerd, waaronder de Philips Shaver Series 1000 die specifiek gericht is op de persoonlijke verzorgingsbehoeften van jonge mannen in China. We hebben ook onze volgende generatie IntelliSpace Portal-werkruimte voor geavanceerde visualisatie geïntroduceerd met AI-mogelijkheden ter ondersteuning van een nauwkeurige diagnose. Om onze Connected Care-oplossingen uit te breiden, hebben we overeenkomsten getekend om BioTelemetry en Capsule Technologies over te nemen. Deze acquisities zullen de oplossingen van Philips voor patiëntzorgbeheer voor het ziekenhuis en thuis verder verbreden en opschalen om de resultaten voor de patiënt te verbeteren, klinische workflows te stroomlijnen en de productiviteit te verhogen. We mikken op aanzienlijke omzetsynergieën en deze activiteiten zullen bijdragen aan de omzetgroei en de gecorrigeerde EBITA-marge van Philips in 2021. Dit is weer een belangrijke stap in onze strategie om een toonaangevende leverancier van oplossingen te worden.

Als gevolg van onze sterkere resultaten in de tweede helft van het jaar, na een uitdagende eerste helft als gevolg van de impact van COVID-19, waren onze prestaties veerkrachtig. Voor het volledige jaar 2020 realiseerden we 3% vergelijkbare omzetgroei, een gecorrigeerde EBITA-marge van 13,2% en een sterke vrije kasstroom van EUR 1,9 miljard. Bovendien, gedreven door een vergelijkbare groei van de orderontvangst van 9%, bleven we marktaandeel winnen in onze gezondheidszorgactiviteiten en sloten we het jaar af met een sterk orderboek.

Ik ben erg dankbaar en trots op de toewijding, vindingrijkheid en het harde werk van onze meer dan 80.000 medewerkers in 2020. Door onze inspanningen konden we onze drievoudige zorgplicht nakomen - het beantwoorden van kritieke behoeften bij onze klanten, het zekerstellen van de veiligheid en gezondheid van onze medewerkers en het borgen van de bedrijfscontinuïteit.

Vooruitkijkend blijven we onzekerheid zien met betrekking tot de impact van COVID-19 over de hele wereld. Voor 2021 is Philips van plan om een lage eencijferige vergelijkbare omzetgroei te realiseren, aangedreven door solide groei in Diagnosis & Treatment en Personal Health, deels tenietgedaan door een lagere Connected Care-omzet, en een verbetering van de gecorrigeerde EBITA-marge van 60-80 basispunten."

Business segment performance


The Diagnosis & Treatment businesses returned to growth, with 1% comparable sales growth in the quarter, driven by high-single-digit growth in Diagnostic Imaging. Comparable order intake showed a 3% increase, compared to a 5% decrease in the previous quarter. The Adjusted EBITA margin decreased to 14.0%, mainly due to mix changes. For the full year, the Diagnosis & Treatment businesses recorded a 2% comparable sales decrease and an Adjusted EBITA margin of 10.0%.

Comparable sales in the Connected Care businesses increased 24% in the quarter, with double-digit growth in Monitoring & Analytics and Sleep & Respiratory Care. Comparable order intake showed a 17% increase, with strong growth across all businesses. The Adjusted EBITA margin increased to 27.2%, due to operating leverage and productivity programs. For the full year, the Connected Care businesses delivered 22% comparable sales growth and an Adjusted EBITA margin of 21.5%.

The Personal Health businesses delivered a comparable sales increase of 5% in the quarter, with double-digit growth in Domestic Appliances and mid-single-digit growth in Personal Care. The Adjusted EBITA margin was 20.0%, in line with Q4 2019. For the full year, the Personal Health businesses recorded a 4% comparable sales decline and an Adjusted EBITA margin of 13.0%.


Philips’ ongoing focus on innovation and partnerships resulted in the following key developments in the quarter and the year:


  • In 2020, Philips’ products and solutions improved the lives of 1.75 billion people, compared to 1.64 billion in 2019. This figure includes 207 million people in underserved communities, compared to 194 million in 2019. In addition, Philips was once again recognized in 2020 for its sustainability performance in the 2020 Dow Jones Sustainability Indices and CDP's Climate Change A-list.

  • Philips signed 25 new long-term strategic partnerships in the quarter, including a 5-year technology and innovation partnership with Rennes University Hospital, one of the top 10 hospitals in France, with four sites and more than 1,800 beds. Philips will deliver integrated solutions to support a precision diagnosis, image-guided therapies, and patient monitoring and management. This includes consultancy services to help optimize the hospital’s clinical pathways.

  • Expanding its range of patient-centric solutions for the home, Philips launched the BiPAP A40 EFL non-invasive ventilator. With this introduction, Philips is extending its respiratory care solutions with a new ventilation therapy feature to treat COPD patients with expiratory flow limitation (EFL) with targeted therapy to reduce symptoms and increase their comfort while sleeping.

  • Highlighting the company’s strength in enterprise imaging solutions, Philips created a single system for all 12 hospitals in the Region of Southern Denmark to store, retrieve, and view radiology and nuclear medicine images and data. This unified imaging ecosystem, which comprises Philips’ Vendor-Neutral Archive and Universal Viewer, will serve all of the region’s radiologists and nuclear medicine specialists, improving collaboration and enhancing patient care.

  • Leveraging Philips’ remote patient monitoring capabilities, Philips and BioIntelliSense have been selected by the U.S. Department of Defense to validate BioIntelliSense’s BioSticker sensor for the early detection of COVID-19 symptoms. The validation study aims to accelerate the use of wearable diagnostics for the early identification and containment of pre-symptomatic COVID-19 cases.

  • Highlighting its leadership in image-guided therapy, there was strong demand for Philips’ mobile surgery solutions, including the Philips Zenition mobile C-arm platform, resulting in double-digit growth for this category during the quarter. Earlier in the year, Philips introduced several new innovations on its Zenition platform to improve the workflow of complex surgical procedures.

  • Philips launched a vendor-neutral, multimodality Radiology Operations Command Center to enable real-time, remote collaboration between technologists, radiologists and imaging operations teams across multiple sites, with the aim of increasing productivity, minimizing issues with image quality, and expanding access to MR- and CT-based diagnosis.

Cost savings

 

In the fourth quarter of 2020, cost savings totaled EUR 123 million, with procurement savings of EUR 67 million and savings from overhead and other productivity programs of EUR 56 million, resulting in annual savings of EUR 447 million in 2020. As a result, Philips has delivered EUR 1.9 billion productivity savings for the Group over the 2017-2020 period, exceeding the target of EUR 1.8 billion.

Report

Fourth Quarter Results 2020 - Report

Presentation

Fourth Quarter Results 2020 - Results Presentation

 

Conference call and audio webcast

A conference call with Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, to discuss the results will start at 10:00AM CET, January 25, 2021. A live audio webcast of the conference call will be available through the link below.

Q4 2020 – Fourth quarter and full year 2020 results conference call audio webcast

 

More information about Frans van Houten and Abhijit Bhattacharya

 

Click here for Mr. van Houten's CV and images

Click here for Mr. Bhattacharya's CV and images


Visit our interactive results hub for more on our financial and sustainability performance over the past quarter, including the latest version of our dynamic Lives Improved world map.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Klik hier voor meer informatieKlik hier voor minder informatie

Forward-looking statements and other important information

 

Forward-looking statements


This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include: statements made about the strategy; estimates of sales growth; future Adjusted EBITA; future restructuring, acquisition-related and other costs; future developments in Philips’ organic business; and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

 

These factors include but are not limited to: changes in industry or market circumstances; economic and political developments; market and supply chain disruptions due to the COVID-19 outbreak; Philips’ increasing focus on health technology; the realization of Philips’ growth ambitions and results in growth geographies; successful completion of divestments such as the divestment of our Domestic Appliances businesses; lack of control over certain joint ventures; integration of acquisitions; securing and maintaining Philips’ intellectual property rights and unauthorized use of third-party intellectual property rights; compliance with quality standards, product safety laws and good manufacturing practices; exposure to IT security breaches, IT disruptions, system changes or failures; supply chain management; ability to create new products and solutions; attracting and retaining personnel; financial impacts from Brexit; compliance with regulatory regimes, including data privacy requirements; governmental investigations and legal proceedings with regard to possible anticompetitive market practices and other matters; business conduct rules and regulations; treasury risks and other financial risks; tax risks; costs of defined-benefit pension plans and other post-retirement plans; reliability of internal controls, financial reporting and management process. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2019.

 

Third-party market share data

 

Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.

 

Use of non-IFRS information

 

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2019.

 

Use of fair value information

 

In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2019. In certain cases independent valuations are obtained to support management’s determination of fair values.

 

Presentation

 

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the significant accounting policies as stated in the Annual Report 2019.

Effective Q1 2020, Philips has simplified its order intake policy by aligning horizons for all modalities to 18 months to revenue, compared to previously used delivery horizons of 6 months for Ultrasound, 12 months for Connected Care and 15 months for Diagnosis & Treatment. At the same time, Philips has aligned order intake for software contracts to the same 18 months to revenue horizon, meaning that only the next 18 months conversion to revenue under the contract is recognized, compared to the full contract values recognized previously. This change eliminates major variances in order intake growth and better reflects expected revenue in the short term from order intake booked in the reporting period. This realignment has not resulted in any material additional order intake recognition.

In 2020, Philips revised the definition of net finance expenses used in the calculation of Adjusted income from continuing operations attributable to shareholders, to exclude fair value movements of limited life fund investments recognized at fair value through profit and loss. This change leads to more relevant information as the fair value movements are not indicative of Philips' performance. The fair value movements do not represent cash items. Philips believes making this change is helpful for investors to evaluate Philips' performance.

Per share and weighted average share calculations have been adjusted for all periods presented to reflect the issuance of shares for the share dividend in respect of 2019.

Prior-period amounts have been reclassified to conform to the current-period presentation.

 

Market Abuse Regulation

 

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Klik hier voor meer informatieKlik hier voor minder informatie

Onderwerpen

Contact

Ben Zwirs

Ben Zwirs

Philips Global Press Office

Tel: +31 6 1521 3446

Martijn van der Starre

Martijn van der Starre

Philips Global Press Office

Tel: +31 6 2847 4617

Business Highlights Q4 2020

Business Highlight In 2020, Philips’ products and solutions improved the lives of 1.75 billion people, compared to 1.64 billion in 2019. This figure includes 207 million people in underserved communities, compared to 194 million in 2019.
Expanding its range of patient-centric solutions for the home, Philips launched the BiPAP A40 EFL non-invasive ventilator.
Business Highlights - Philips signed 25 new long-term strategic partnerships in the quarter, including a 5-year technology and innovation partnership with Rennes University Hospital, one of the top 10 hospitals in France, with four sites and more than 1,800 beds.
Philips signed 25 new long-term strategic partnerships in the quarter, including a 5-year technology and innovation partnership with Rennes University Hospital, one of the top 10 hospitals in France, with four sites and more than 1,800 beds.
Business Highlights - Expanding its range of patient-centric solutions for the home, Philips launched the BiPAP A40 EFL non-invasive ventilator.
In 2020, Philips’ products and solutions improved the lives of 1.75 billion people, compared to 1.64 billion in 2019. This figure includes 207 million people in underserved communities, compared to 194 million in 2019.

Deel op social media

U kunt onze website het beste bekijken met de nieuwste versie van Microsoft Edge, Google Chrome of Firefox.